Logotype for RaySearch Laboratories

RaySearch Laboratories (RAY) Q1 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for RaySearch Laboratories

Q1 2026 earnings summary

30 Apr, 2026

Executive summary

  • Q1 2026 saw net sales decline to SEK 290 million, down 20% year-over-year, mainly due to currency effects and a tough comparison with a large prior-year order from China, but profitability remained robust with an operating profit of SEK 68 million and a 23% margin.

  • Recurring support revenue provided stability, accounting for 42% of total revenue.

  • Several strategically important deals were secured, including first RayCare orders in China and France, and continued conversions in Germany; RayStation began treating patients in Ukraine.

  • Demand for integrated and automated cancer care workflows remains strong, with a solid sales pipeline and growing interest in online adaptive solutions.

  • The company is preparing for the first online adaptive treatments with RayStation, RayCare, and TrueBeam.

Financial highlights

  • Net sales declined 20% year-over-year to SEK 290 million, with organic growth at -5%.

  • Order intake dropped 13% compared to last year, affected by currency and a strong prior-year quarter.

  • Book-to-bill ratio was 1.2; order backlog at end of March was SEK 1,615 million, with SEK 624 million expected to convert to sales in the next 12 months.

  • License sales decreased 24% and support sales by 1% year-over-year; support revenue would have grown 8% excluding currency effects.

  • Cash balance at quarter-end was SEK 439 million; cash flow was stable despite inventory pre-purchasing to mitigate hardware price increases.

Outlook and guidance

  • Several delayed orders are expected to be recognized in Q2 or Q3, supporting a return to growth.

  • Confident in achieving at least a 25% operating margin for full year 2026 and a new long-term target of at least 30% by 2028.

  • No concerns about growth fading in 2027 despite Pinnacle³ conversion window closing.

  • Management expects continued strong demand for integrated and automated cancer care workflows, with a robust sales pipeline.

  • Revenues may fluctuate quarterly, but the long-term growth trend is positive.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more